Journal article · 2023 · Open access
1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism
Journal for ImmunoTherapy of Cancer, A1561 · Published 31 October 2023 · DOI 10.1136/jitc-2023-sitc2023.1403
In brief
“1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism” is a 2023 journal article by Zhenqing Zhang and 6 co-authors, published in Journal for ImmunoTherapy of Cancer. OpenAlex counts 3 citations as of 18 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Journal for ImmunoTherapy of Cancer.
- Citations
- 3
- Most cited in
- 2025 (2)
- Authors
- 7
Abstract
Background The discovery and development of first-generation immune checkpoint inhibitors (towards PD1 and CTLA-4) reached a major milestone for cancer therapy. CD40, as a member of the TNFR superfamily, plays a vital role in stimulating DC and B cell maturation and has been targeted to improve on existing immuno-oncology treatments. Due to potential systemic toxicity risks by targeting CD40 via agonist antibodies, new and emerging strategies have focused on localizing agonism to the tumor microenvironment.Methods We have constructed a novel bispecific antibody towards PD1 and CD40, which were generated by fusing anti-CD40 scFvs to the C-terminus of an anti-PD1 IgG. Fc silencing was adopted to reduce effector function towards PD1- and CD40-expressing immune cells. Furthermore, anti-CD40 non-blocking antibodies were selected based on high agonist activity via receptor cross-linking but with non-ligand blocking properties to reduce any unwanted dampening of natural CD40-CD40L activity. Cell binding, receptor-ligand blockade, luciferase-based reporter assays, and primary B cell assays, were used for selecting and characterizing lead bispecific candidates. Mixed lymphocyte reactions were also performed to test for enhancing effects towards T cells. Finally, our lead candidates were evaluated in in vivo efficacy studies on MC38 and A375 tumor cell lines in syngeneic and PBMC-based models, respectively.Results In vitro experiments showed that the lead anti-PD1 x CD40 bispecific could disrupt potently the interaction between PD1 and PD-L1. In addition, CD40 signal activation was detected using an NFkB luciferase reporter assay and in primary B cells, which was dependent on PD1-based cross-bridging/cross-linking. Thus, besides promoting the conditional activation of CD40 in the tumor microenvironment and tumor-draining lymph nodes where PD1 expression is upregulated, potential toxicity risks have been substantially reduced by screening away any superagonist traits when selecting for the anti-CD40 component. The anti-PD1 x CD40 bispecific also showed enhanced T cell responses than anti-PD1 alone or the combination of anti-PD1 and anti-CD40 antibodies in an MLR assay. Using in vivo tumor models, CD40-CD40L non-blocking, PD1-based bispecific candidates, displayed better anti-tumor efficacy than anti-PD1 alone or the combination of anti-PD1 and anti-CD40 antibodies. Furthermore, anti-PD1 x CD40 bispecific antibodies did not induce any untoward toxicity in MC38-bearing human-PD1/CD40 double knock-in mice.Conclusions Collectively, these data demonstrate that anti-PD1 x CD40 bispecific antibodies are promising beyond PD1 inhibitors. As such, we have selected a final candidate that is undergoing CMC development for entering the clinic.Acknowledgements We would like to acknowledge our collaborator Adimab for generating the anti-PD1 and anti-CD40 mAbs on the Adimab Platform.Ethics Approval All mice were maintained under specified pathogen-free conditions, and all studies were approved by…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zhang, Z., Jia, Y., Huang, W., Wang, C., Jiang, W., Li, Z., & Tsun, A. (2023). 1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism. Journal for ImmunoTherapy of Cancer, A1561. https://doi.org/10.1136/jitc-2023-sitc2023.1403
MLA 9
Zhang, Zhenqing, et al. “1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism.” Journal for ImmunoTherapy of Cancer, 2023, p. A1561. https://doi.org/10.1136/jitc-2023-sitc2023.1403.
Chicago
Zhang, Zhenqing, Yunli Jia, Weifeng Huang, Chao Wang, Wenchao Jiang, Zhiyuan Li, and Andy Tsun. 2023. “1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism.” Journal for ImmunoTherapy of Cancer: A1561. https://doi.org/10.1136/jitc-2023-sitc2023.1403.
Harvard
Zhang, Z. et al. (2023) ‘1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism’, Journal for ImmunoTherapy of Cancer, p. A1561. doi:10.1136/jitc-2023-sitc2023.1403.
IEEE
Z. Zhang et al., “1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism,” Journal for ImmunoTherapy of Cancer, p. A1561, 2023, doi: 10.1136/jitc-2023-sitc2023.1403.
BibTeX
@article{zhang2023bispecific,
title = {{1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism}},
author = {Zhang, Zhenqing and Jia, Yunli and Huang, Weifeng and Wang, Chao and Jiang, Wenchao and Li, Zhiyuan and Tsun, Andy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
pages = {A1561},
doi = {10.1136/jitc-2023-sitc2023.1403},
url = {https://doi.org/10.1136/jitc-2023-sitc2023.1403}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- PD-1
- CD40
- immune checkpoint blockade
- CD40 agonism
- PD-1/PD-L1 blockade
- tumor microenvironment
- receptor cross-linking
- T cell activation
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Zhang, Z., Jia, Y., Huang, W., Wang, C., Jiang, W., Li, Z., & Tsun, A. (2023). 1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism. Journal for ImmunoTherapy of Cancer, A1561. https://doi.org/10.1136/jitc-2023-sitc2023.1403
How many times has this paper been cited?
3 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal for ImmunoTherapy of Cancer: sign in and open the PDF from this page.
Who wrote this paper?
Zhenqing Zhang, Yunli Jia, Weifeng Huang, Chao Wang, Wenchao Jiang, Zhiyuan Li, Andy Tsun.
What is the DOI of this paper?
10.1136/jitc-2023-sitc2023.1403, permanently at https://doi.org/10.1136/jitc-2023-sitc2023.1403. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.